<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807196</url>
  </required_header>
  <id_info>
    <org_study_id>ZEV0701</org_study_id>
    <nct_id>NCT00807196</nct_id>
  </id_info>
  <brief_title>Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma</brief_title>
  <official_title>Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the ability to combine a radioactive medication&#xD;
      directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem&#xD;
      cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite initial high response rates of low grade Non Hodgkin lymphoma, progressive or&#xD;
      refractory disease currently remains incurable. Being a radiosensitive tumor, we hypothesize&#xD;
      that combining different modalities of treatment including targeted radioimmunotherapy (RIT),&#xD;
      and a graft versus lymphoma effect related to an allogeneic non myeloablative stem cell&#xD;
      transplant may increase response and survival rates in a safe manner in patients with&#xD;
      persistent disease following initial treatment. In this study patients who are not eligible&#xD;
      for a standard stem cell transplant approach because of relapsed or refractory disease and&#xD;
      who have a related sibling donor are treated with RIT followed by an allogeneic non&#xD;
      myeloablative blood stem cell transplant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment, chimerism, transplant related toxicity, acute and chronic GVHD</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate, overall and disease free survival</measure>
    <time_frame>360 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-Hodgkins Lymphoma</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>250mg/m2 day -21 and day -14 of preparative regimen</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y ibritumomab tiuxetan (Zevalin)</intervention_name>
    <description>0.4 mCi/kg IV on day -14 of preparative regimen</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non myeloablative allogeneic stem cell transplantation</intervention_name>
    <description>Blood stem cell infusion on day 0</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must have/be&#xD;
&#xD;
          1. Age 18 to 65 years. Patients between age 66 and 69 may be enrolled if judged to be in&#xD;
             excellent physical condition as per treating physician and study investigator and&#xD;
             based on institutional practice.&#xD;
&#xD;
          2. Diagnosis of Non-Hodgkin lymphoma, follicular, marginal zone, small lymphocytic&#xD;
             lymphoma, mantle cell lymphoma or transformed from an indolent NHL to aggressive&#xD;
             histology disease lymphoma as defined by the World Health Organization.&#xD;
&#xD;
          3. Disease relapsed after, refractory or failing to achieve a PR after two or more cycles&#xD;
             of intensive salvage chemotherapy (R-ESHAP or other) or disease relapsed after&#xD;
             autologous stem cell transplantation. Poor partial response is defined as less than&#xD;
             50% reduction of tumor size. Salvage chemotherapy has to be administered after either&#xD;
             1st, 2nd or 3rd relapse&#xD;
&#xD;
          4. Disease expressing the CD 20 antigen&#xD;
&#xD;
          5. ECOG performance status 0-2&#xD;
&#xD;
          6. Judged to be able to tolerate NST and Zevalin treatment based on institutional&#xD;
             criteria.&#xD;
&#xD;
          7. Signed written informed consent&#xD;
&#xD;
          8. At least one fully HLA matched sibling without evident contraindications to the&#xD;
             donation procedures and willing to sign consent for donation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients must not have/be&#xD;
&#xD;
          1. Abnormal renal function (creatinine &gt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          2. Abnormal hepatic function (bilirubin &gt; 2 x ULN, ALT/AST&gt;2x ULN)&#xD;
&#xD;
          3. Cardiac ejection fraction &lt;40% and/or other significant cardiac compromise&#xD;
&#xD;
          4. Severe defects in pulmonary function tests or receiving continuous oxygen&#xD;
&#xD;
          5. Severe concurrent illness, such as symptomatic congestive heart failure, severe&#xD;
             arrhythmias, uncontrolled hypertension, diabetes, severe neurologic or psychiatric&#xD;
             disorder or known HIV positive&#xD;
&#xD;
          6. Previous or concurrent cancer that is distinct in primary site or histology from the&#xD;
             cancer being evaluated except cervical carcinoma in situ, treated basal cell&#xD;
             carcinoma, superficial bladder tumors (Ta, Tis &amp; T1) that may impact on patients life&#xD;
             expectancy or any cancer curatively treated &lt; 3 years prior to study entry.&#xD;
&#xD;
          7. History of prior allogeneic bone marrow transplant&#xD;
&#xD;
          8. Evidence of active hepatitis B or C infection or positivity for hepatitis-B surface&#xD;
             antigen&#xD;
&#xD;
          9. Known type 1 hypersensitivity or anaphylactic proteins to any component of the Zevalin&#xD;
             therapy or a history or presence of human anti-mouse antibodies (HAMA)&#xD;
&#xD;
         10. A female patient who is pregnant or breast feeding and an adult of reproductive&#xD;
             potential who is not employing an effective method of birth control during the study.&#xD;
&#xD;
         11. CNS lymphoma&#xD;
&#xD;
         12. Ongoing confirmed or suspected significant infection&#xD;
&#xD;
         13. Prior treatment with radioimmunotherapy&#xD;
&#xD;
         14. Other condition preventing participation in standard NST&#xD;
&#xD;
         15. No fully matched sibling donor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Kiss, MD</last_name>
    <phone>514-252-3404</phone>
    <email>thomas.kiss@umomtreal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2V 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kiss, MD</last_name>
      <phone>(514)252-3404</phone>
      <email>thomas.kiss@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Beaupré, BSc nursing</last_name>
      <phone>(514)252-3400</phone>
      <phone_ext>5605</phone_ext>
      <email>dbeaupré.hmr@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Kiss, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>December 10, 2008</last_update_submitted>
  <last_update_submitted_qc>December 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Carole Deschambault/executive director</name_title>
    <organization>Hopital Maisonneuve-Rosemont</organization>
  </responsible_party>
  <keyword>Allogeneic Stem Cell Transplantation</keyword>
  <keyword>Zevalin</keyword>
  <keyword>Non-Hodgkins Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

